PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2063989
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2063989
According to Mordor Intelligence, the eggshell membrane market size is projected to be USD 204.65 million in 2025, USD 224.09 million in 2026, and reach USD 352.77 million by 2031, growing at a CAGR of 9.65% from 2026 to 2031.

This report is Segmented by Type (Hydrolyzed, Unhydrolyzed), Product Form (Powder, Capsules, Tablets, Liquid Formats), Application (Nutraceuticals, Cosmetics and Personal Care, Food and Beverages, Pharmaceuticals, Animal Nutrition and Pet Supplements), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
The global osteoarthritis burden, driven by aging populations and obesity-related joint stress, is significantly boosting the eggshell membrane market. In 2024, 607 million people globally were affected by osteoarthritis, with prevalence rates projected to rise by 2050. East Asia, where knee osteoarthritis accounts for 73% of cases, represents a key growth region. Middle-income economies expanding access to non-pharmacological joint support present strong near-term opportunities. The NEM brand eggshell membrane differentiates itself by reducing the cartilage degradation biomarker CTX-II by 19.2% within a week, outperforming slower-acting alternatives like glucosamine and chondroitin.
The eggshell membrane market benefits from its alignment with clean-label trends and the appeal of upcycled ingredients. Eggshell membrane, sourced from industrial egg-breaking streams, supports sustainability by diverting billions of eggshells from landfills annually. Over 800 products have achieved Upcycled Certified status, reflecting mainstream acceptance of this model. Suppliers emphasizing environmental performance gain an edge with multinational brands focused on ESG compliance. Eggnovo SL's negative carbon footprint further strengthens the eggshell membrane's premium positioning over lower-cost substitutes like bovine collagen and glucosamine.
The eggshell membrane market faces supply challenges as raw membrane availability depends on industrial egg-breaking operations. In Q1 2025, nearly 40 million poultry were lost to avian influenza in the U.S., with recovery expected to take 9 months to a year if outbreaks remain contained. Since eggshell membrane is a byproduct, reduced egg-processing throughput lowers availability and increases fixed costs per unit. Cost pressures intensify when egg prices fluctuate, as seen with a spike to USD 8/dozen in February 2025 before dropping to USD 3/dozen in March. European suppliers, like Eggnovo SL, are investing in process improvements, but the market is likely to face sustained cost challenges in the near term.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
In 2025, hydrolyzed eggshell membrane held 67.40% of the market, driven by its established role in joint health nutraceuticals. Its market leadership is supported by extensive clinical validation, such as ESM Technologies' NEM, which has been studied in over 10 human clinical trials for joint comfort and flexibility. While hydrolyzed formats remain central to revenue, unhydrolyzed eggshell membrane is forecast to grow at a 10.24% CAGR from 2026 to 2031, fueled by its increasing use in skin and beauty applications. Stratum Nutrition's Ovolux, launched in 2025, demonstrated significant improvements in skin elasticity and firmness, highlighting the growing segmentation between hydrolyzed forms for joint support and unhydrolyzed forms for beauty products. Denk Ingredients' expanded ESM(R) range reflects how suppliers are diversifying portfolios to capture both market segments.
In 2025, North America led the eggshell membrane market with a 37.65% share. The region's mature supplement retail system, strong acceptance of clinically-claimed products, and the presence of key domestic suppliers like ESM Technologies, Biova LLC, and Stratum Nutrition drive its dominance. These factors enable faster commercialization, supported by established connections between ingredient developers, product brands, and retail channels.
Europe is the second-largest market for eggshell membranes, with growth previously constrained by regulatory delays rather than demand. Biova's EU Novel Foods approval in July 2024 allowed European brands to use U.S.-sourced eggshell membranes with fewer regulatory barriers. Additionally, investments like Eggnovo SL's factory upgrades for processing enhance local supply resilience, positioning Europe for balanced growth in demand and supply.
Asia-Pacific is projected to grow at a CAGR of 11.45% from 2026 to 2031, making it the fastest-growing region in the eggshell membrane market. Japan leads with a mature market supported by product recognition and research collaborations. South Korea's high osteoarthritis incidence and China's rising burden create significant opportunities, while India's FSSAI approval for NEM facilitates premium joint supplement launches. The Middle East, Africa, and South America remain smaller markets but show potential due to improving retail systems and growth in Brazil's nutraceutical sector.